Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study-Reference-Cited by-同舟云学术

Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study

Published:2012-01-17 Issue:3 Volume:34 Page:297-303
ISSN:0886-022X
Container-title:Renal Failure
language:en
Short-container-title:Renal Failure

Author:

Tonbul Halil Zeki,Solak Yalcin,Atalay Huseyin,Turkmen Kultigin,Altintepe Lutfullah

Publisher

Informa UK Limited

Subject

Nephrology,Critical Care and Intensive Care Medicine,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/0886022X.2011.647298

Reference23 articles.

1. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients

2. Vitamin D Deficiency and Secondary Hyperparathyroidism Among Patients with Chronic Kidney Disease

3. Consequences and management of hyperphosphatemia in patients with renal insufficiency

4. Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

5. New Vitamin D analogs and changing therapeutic paradigms

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary Hyperparathyroidism (SHPT);Case Studies in Thyroid and Parathyroid Tumors;2023

2. Selective vitamin D receptor activator Paricalcitol and its potential benefits in hemodialysis patients with secondary hyperparathyroidism;Meditsinskiy sovet = Medical Council;2022-06-19

3. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis;Frontiers in Public Health;2021-07-21

4. Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison;Frontiers in Endocrinology;2019-02-05

5. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment;Therapeutic Apheresis and Dialysis;2018-12-18